ONN^® - OncLive News Network^®

Nitin Jain, MD, and Richard R. Furman, MD, review the role of BTK inhibitors and emerging therapies on the horizon for the management of CLL.

Kenneth Shain, MD, PhD reviews advances in treatment of relapsed and refractory multiple myeloma and data presented at 2021 International Myeloma Workshop.

Preferences for conducting molecular testing in patients with chronic lymphocytic leukemia to guide treatment decisions based on evolving novel combination regimens used as frontline therapy.

Expert gynecologic oncologist Rebecca Arend, MD, MPH, addresses data from the 2021 ESMO meeting and the approval of tisotumab vedotin for patients with cervical cancer.

Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, discuss data updates from the TROPION-PanTumor01 study that impact the use of antibody-drug conjugates as a therapy option for patients with second-line metastatic non-small cell lung cancer.

Mark Pegram, MD, and Sara Tolaney, MD, review data from DESTINY-Breast03 trial and implications of these data for treatment of patients with HER2+ breast cancer going forward.

The second part of the webinar Lung Cancer Screening and Treatment: What's Next? focuses on the review of lung cancer screening and treatment status amid the COVID-19 pandemic. Participating faculty include Albert Rizzo, MD, FCCP, FACP, FAASM; James L. Mulshine, MD; Andrea Borondy Kitts, MS, MPH; and Sandip Patel, MD.

An expert hematologist/oncologist will highlight the traditional treatment options, unmet needs, and recent advances and approvals in chronic graft vs host disease. Clinical trials will be described as well as novel agents on the horizon.

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, discuss adverse events associated with treating chronic lymphocytic leukemia, particularly when utilizing BTK inhibitors.

Implications for treating patients with progressive, unresectable locally advanced or metastatic HER2-positive breast cancer with tucatinib in combination with capecitabine and trastuzumab.

Experts share their perspective on the optimal management of chronic lymphocytic leukemia in light of recent clinical data for novel targeted therapies.

Expert thoracic oncologists discuss the importance of comprehensive molecular testing and optimal use of novel targeted agents in metastatic non-small cell lung cancer.

Key opinion leaders in the treatment of myeloproliferative neoplasms, Pankit Vachhani, MD, and Jamile Shammo, MD, share expert perspectives on ruxolitinib for patients with primary myelofibrosis and polycythemia vera.

The rationale behind the use of lutetium-177-PSMA-617, a targeted radioligand therapy, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Experts discuss recent data on next generation sequencing and germline testing in patients with advanced and metastatic cancer.

Drs Richard D. Carvajal and Marlana M. Orloff describe the rationale for treating uveal melanoma with tebentafusp and provide insight on assessing treatment response and managing treatment-related adverse events.

Glenn Hanna, MD, and Nabil F. Saba, MD, FACP, discuss recent data on use of tipifarnib in HRAS-mutant head and neck squamous cell carcinoma.

Sara A. Hurvitz, MD, discusses updated results of the HER2CLIMB trial of tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer.